Adalimumab (TNFα Inhibitor) Therapy Exacerbates IgA Glomerulonephritis Acute Renal Injury and Induces Lupus Autoantibodies in a Psoriasis Patient

Adalimumab (Humira) is a tumour necrosis factor α (TNFα) inhibitor that is approved for the treatment of rheumatoid arthritis, psoriasis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis, and juvenile idiopathic arthritis (Sullivan and Preda (2009), Klinkhoff (2004), and Medicare Au...

Full description

Saved in:
Bibliographic Details
Main Authors: S. S. Wei, R. Sinniah
Format: Article
Language:English
Published: Wiley 2013-01-01
Series:Case Reports in Nephrology
Online Access:http://dx.doi.org/10.1155/2013/812781
Tags: Add Tag
No Tags, Be the first to tag this record!